Loading...
StocksRunner logo
 
 
Adaptimmune Therapeu
1.03
-4.17%
 
ADAP Adaptimmune Therapeutics
Last Price
Change
1.03
 
-4.17%
 
 
 

 
Sentiment
 
  Login to display
 
 

1.36

1.12

1.87

1.62

 
 
1m
3m
6m
1y
 

Summary

Adaptimmune Therapeutics (ADAP) still has no score becuse there is not enough information which allows us to analyze the activity of the stock over a period of time
 

Strengths

Rewards

 Upgraded on attractively valued

 
 

Risk Level

 
StocksRunner
 

Adaptimmune Therapeutics (ADAP) has Extreme Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

4.00
 
 
 

Rating

×
 

Rating

5.00
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

NA
 
 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

NA
 
 
 

Analysts Opinion

Analysts opinion is negative but has improved from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
100%
100%
NA
NA
 
On Track
On Track
On Track
 

Street Opinion 

Street view is extremely ish and have negative views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
100%
0%
Positive
Negative
6 out of 6
events present
0 out of 6
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Partnership
This Week
1.09
+6.86%
 
Partnership
2 Month Ago
1.35
-4.61%
 
Buy Rating
2 Month Ago
1.39
+2.21%
 
Top Headlines

adaptimmune completes merger with fellow immunology company tcr2.

Thu Jun 1, 2023

Activity

adaptimmune shareholders can lock in a big merger spread by swapping to tcr2 therapeutics.

Fri Apr 21, 2023

Activity

ef hutton reiterates adaptimmune therapeutics (adap) buy recommendation. fintel reports that on april 17 2023 ef hutton reiterated coverage of adaptimmune therapeutics (nasdaq:adap) with a buy

Mon Apr 17, 2023

Rating

adaptimmune (adap) up 7% gets t-cell programs rights from gsk. adaptimmune therapeutics plcadap announced entering into a transition agreement with gsk plc gsk to ensure the return of rights and materials comprised within the prame and

Wed Apr 12, 2023

Activity

ef hutton reiterates adaptimmune therapeutics (adap) buy recommendation. fintel reports that on april 11 2023 ef hutton reiterated coverage of adaptimmune therapeutics (nasdaq:adap) with a buy

Tue Apr 11, 2023

Rating

why shares of adaptimmune therapeutics jumped tuesday. what happened shares of adaptimmune therapeutics (nasdaq: adap) were up as much as 9.7% early tuesday after the clinical-stage biotech announced that it had reached an agreement with gsk (n

Tue Apr 11, 2023

Activity

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily ADAP alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

ADAP Adaptimmune Therapeutics

Last Price
1.03
Change
-4.17%
 

Summary

Adaptimmune Therapeutics (ADAP) still has no score becuse there is not enough information which allows us to analyze the activity of the stock over a period of time

 
 
1.36
1.12
1.87
1.62
 
 
1m
3m
6m
1y
 
Sentiment
 

  Login to display

Strengths

Rewards

 Upgraded on attractively valued

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
100%
NA
NA
On Track
On Track
On Track
 
100%
0%
Positive
Negative
6 out of 6
events present
0 out of 6
events present
 

Street Opinion

Street view is extremely ish and have negative views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

4.00
 
 
 

Rating

×
 

Rating

5.00
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

NA
 
 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

NA
 
 
 

Analysts Opinion

Analysts opinion is negative but has improved from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

Adaptimmune Therapeutics (ADAP) has Extreme Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Partnership
This Week
1.09
+6.86%
 
Partnership
2 Month Ago
1.35
-4.61%
 
Buy Rating
2 Month Ago
1.39
+2.21%
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily ADAP Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines